Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age

Area of Science:

• Hepatobiliary oncology
• Medical oncology
• Pharmacology

Background:

• Sorafenib is the sole systemic therapy demonstrating survival benefits in advanced hepatocellular carcinoma (HCC).
• Key questions persist regarding sorafenib's clinical application, including predicting patient response and managing treatment beyond progression.
• The landscape of HCC treatment is evolving with numerous novel agents under investigation.

Purpose of the Study:

• To review the current therapeutic applications of sorafenib in advanced hepatocellular carcinoma (HCC).
• To elucidate clinical parameters and biomarkers that predict sorafenib efficacy.
• To discuss the continuation of sorafenib beyond radiological progression and its expanded applications.

Main Methods:

• Extensive literature review of sorafenib in advanced hepatocellular carcinoma (HCC).
• Analysis of studies on predictive biomarkers, including serum cytokines and gene amplification.
• Evaluation of research on sorafenib continuation and combination therapies.

Main Results:

• Predictive biomarkers like specific serum cytokines and tumor gene amplification may indicate sorafenib response.
• Continuation of sorafenib beyond progression is a consideration due to lack of alternative standard therapies.
• While numerous new drugs are in development, none have surpassed sorafenib's efficacy, though some show promise post-sorafenib failure.

Conclusions:

• Sorafenib remains a cornerstone therapy for advanced HCC, but personalized treatment strategies are needed.
• Further research is crucial for identifying responders, optimizing treatment duration, and developing effective post-sorafenib therapies.
• The ongoing investigation of novel agents aims to improve outcomes for HCC patients, potentially in combination with or after sorafenib treatment.